BC Week In Review | Aug 27, 2012
Clinical News

AZD8931: Phase Ib/IIa started

Cancer Research UK (London, U.K) said Oxford University began a dose-escalation, open-label, U.K. Phase Ib/IIa trial to compare AZD8931 plus Xelox chemotherapy (a combination of oral Xeloda capecitabine and IV oxaliplatin) vs. Xelox alone in...
BC Week In Review | Jun 11, 2012
Clinical News

Avastin bevacizumab cancer data

The GE Healthcare unit of General Electric Co. (NYSE:GE, Fairfield, Conn.) and colleagues reported data from a model-based study showing that biomarker-directed use of Avastin, in which an in vivo biomarker test is used to...
BC Week In Review | Oct 18, 2010
Clinical News

Avastin bevacizumab: Development discontinued

Roche said it discontinued development of Avastin for adjuvant colorectal cancer after it missed the primary endpoints in 2 previously reported Phase III trials in the indication (see BioCentury, April 27, 2009 & Sept. 27,...
BC Week In Review | Sep 27, 2010
Clinical News

Avastin bevacizumab: Phase III data

Top-line data from the Phase III AVANT trial in 3,451 patients who had undergone surgery for high-risk stage II and III colon cancer showed that Avastin plus FOLFOX or XELOX chemotherapy missed the primary endpoint...
BC Week In Review | May 31, 2010
Clinical News

Recentin cediranib: Phase III data

Top-line data from the double-blind, international Phase III HORIZON II trial in 1,050 first-line mCRC patients showed that Recentin plus FOLFOX or XELOX chemotherapy met the co-primary endpoint of significantly improving PFS vs. placebo plus...
BC Extra | May 29, 2010
Clinical News

Mixed results for Recentin in mCRC

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Recentin cediranib met one co-primary endpoint but missed the other in the Phase III HORIZON II trial to treat metastatic colorectal cancer (mCRC). Recentin plus FOLFOX or XELOX significantly improved...
BC Week In Review | Jan 25, 2010
Clinical News

Xelox: Additional Phase III data

Additional data from the open-label, international Phase III NO16968 (XELOXA) trial in 1,886 previously untreated patients showed that Xelox led to 4- and 5-year disease-free survival rates of 68.4% and 66%, respectively, vs. 62.3% and...
BC Week In Review | Dec 7, 2009
Clinical News

Avastin bevacizumab regulatory update

The U.K.'s NICE issued a preliminary appraisal recommending against the use of Avastin bevacizumab from Roche in combination with oxaliplatin and either 5-fluorouracil plus folinic acid or capecitabine to treat metastatic colorectal cancer. The agency...
BC Week In Review | Oct 5, 2009
Clinical News

Xelox: Additional Phase III data

Additional data from the open-label, international Phase III NO16968 (XELOXA) trial in 1,886 previously untreated patients showed that Xelox led to a 3-year disease-free survival rate of 70.9% compared with 66.5% for 5-fluorouracil (5-FU) plus...
BC Week In Review | Jul 27, 2009
Clinical News

Xelox: Phase III data

Top-line data from the open-label, international Phase III NO16968 trial in 1,886 previously untreated patients showed that Xelox immediately following surgery met the primary endpoint of a significant increase in disease-free survival compared with 5-fluorouracil...
Items per page:
1 - 10 of 24